Tevogen Bio Holdings Inc. TVGN 深 沪
已收盘 02-06 16:00:00 美东时间
0.2746
-0.005
-1.96%
华盛通- 最 高0.2938
- 今 开0.2841
- 成交量 49.79万股
- 最 低 0.2701
- 昨 收 0.2801
- 总市值 5533.80万
- 52周最高 1.67
- 市盈率 静 --
- 换手率 0.25%
- 52周最低 0.252
- 委 比 -46.34%
- 总股本 2.02亿
- 历史最高 21.09
- 量 比 0.35
- 振 幅 8.46%
- 历史最低 0.252
- 每 手 1
- 风险率 0.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tevogen Evaluates Potential One-Time Special Cash Dividend, Subject To Future Financial Milestones
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to
01-31 04:02
Tevogen Bio Ties Long-Term Stock Incentives to Company Milestones
Tevogen Bio Ties Long-Term Stock Incentives to Company Milestones Tevogen Bio Holdings Inc. has announced an update to its long-term stock incentive program, modifying it to align awards with defined company milestones, including revenue. The revised program will apply to all employees, officers, di
01-30 03:45
Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue
Tevogen has modified its long-term stock-based incentive program to align with company milestones, including revenue targets, applicable to all eligible employees and consultants. The company aims to launch at least four blockbuster products by 2030 and generate revenue in 2026 through its programs, potential acquisitions, and joint ventures. Tevogen, a diversified healthcare company, focuses on affordable and efficient therapies, leveraging AI a...
01-29 19:45
Tevogen Reports 2025 Milestones, Expands ExacTcell Platform And Multi-Indication CTL Pipeline; Advances In-House GMP Manufacturing Capabilities
Jan. 12, 2026, San Francisco. Issued from the J.P. Morgan Healthcare ConferenceWARREN, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today reported significant
01-12 22:35
Tevogen Provided Updates At J.P. Morgan Healthcare Conference
Pipeline Expansion Across Multiple Indications:Building on its SARS-CoV-2 proof-of-concept clinical experience, Tevogen completed T cell target identification for five additional HLA restrictions, significantly expanding
01-12 22:09
Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025
Tevogen reported significant achievements in 2025, including enhancements to its ExacTcell™ platform, expansion of its cytotoxic T lymphocyte (CTL) pipeline across viral and oncology indications, and advancements in in-house GMP cell therapy manufacturing capabilities. These milestones reflect the company's progress in scalability, pipeline breadth, and manufacturing readiness, positioning it for future clinical and commercial success. CEO Ryan S...
01-12 14:00
Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
Shares of Heartbeam Inc (NASDAQ:BEAT) rose sharply in pre-market trading after ...
2025-11-28 17:49
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
2025-11-21 15:50
D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Lowers Price Target to $5
D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy and lowers the price target from $10 to $5.
2025-11-20 21:13
Tevogen Expands COVID-19 T Cell Therapy Reach With Multi-HLA Targeting, Expanding Patient Eligibility
This milestone expands patient eligibility through multi-HLA targetingBuilds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk patientsTVGN 489
2025-11-06 04:22
